Last quarter (Q ), AIkido Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, AIkido Pharma's net income was $-6.24M. See AIkido Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	-	$ 0.00	$ 0.00	$ 9.00K	$ 28.00K	$ 1.24M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 13.79M	$ 9.44M	$ 6.55M	$ 5.69M	$ 4.73M	$ 5.06M
Operating Income	$ -13.79M	$ -9.44M	$ -6.55M	$ -5.68M	$ -4.70M	$ -3.82M
Net Non Operating Interest Income Expense	$ 731.00K	$ 252.00K	$ 0.00	-	-	-
Other Income Expense	$ -3.60M	$ 2.02M	$ -5.79M	$ 1.50M	$ 6.43M	$ 516.00K
Pretax Income	$ -16.66M	$ -7.17M	$ -12.34M	$ -4.18M	$ 1.73M	$ -3.31M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -20.77M	$ -7.17M	$ -12.34M	$ -4.18M	$ 1.73M	$ -3.31M
Basic EPS	$ -3.88	$ -1.53	$ -7.48	$ -1.67	$ 0.91	$ -2.55
Diluted EPS	$ -3.88	$ -1.53	$ -7.48	$ -1.67	$ 0.91	$ -2.55
Basic Average Shares	$ 21.13M	$ 4.85M	$ 1.65M	$ 2.51M	$ 1.90M	$ 1.30M
Diluted Average Shares	$ 21.13M	$ 4.85M	$ 1.65M	$ 2.51M	$ 1.90M	$ 1.30M
Dividend Per Share	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	$ 81.00K	$ 92.00K
Total Expenses	$ 13.79M	$ 9.44M	$ 6.55M	$ 5.69M	$ 4.73M	$ 5.06M
Net Income From Continuing And Discontinued Operation	$ -16.66M	$ -7.17M	$ -12.34M	$ -4.18M	$ 1.73M	$ -3.31M
Normalized Income	$ -12.99M	$ -9.05M	$ -6.57M	$ -5.68M	$ -3.21M	$ -3.53M
Interest Expense	-	-	-	-	-	-
EBIT	$ -13.79M	$ -9.44M	$ -6.55M	$ -5.68M	$ -4.70M	$ -3.82M
EBITDA	$ -13.79M	$ -9.44M	$ -6.55M	$ -5.68M	$ -3.26M	$ -2.45M

Currency in USD

AIkido Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing